Mitiglinide
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes. Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Mitiglinide (INN, trade name Glufast) is a drug for the treatment of type 2 diabetes. Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.
Pharmacology
Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium K ATP channels in pancreatic β cells.
Dosage
Mitiglinide is delivered in tablet form.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329360047 under CC BY-SA 4.0; modifications have been made.